RPID has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPID has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-09), Rapid Micro Biosystems's share price is $0.80. Rapid Micro Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.21. Therefore, Rapid Micro Biosystems's PE Ratio for today is At Loss.
Rapid Micro Biosystems's EPS (Diluted) for the three months ended in Mar. 2024 was $-0.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.21.
As of today (2024-05-09), Rapid Micro Biosystems's share price is $0.80. Rapid Micro Biosystems's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.21. Therefore, Rapid Micro Biosystems's PE Ratio without NRI ratio for today is At Loss.
Rapid Micro Biosystems's EPS without NRI for the three months ended in Mar. 2024 was $-0.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.21.
During the past 3 years, the average EPS without NRI Growth Rate was -3.50% per year.
During the past 5 years, Rapid Micro Biosystems's highest 3-Year average EPS without NRI Growth Rate was -3.50% per year. The lowest was -12.90% per year. And the median was -8.20% per year.
Rapid Micro Biosystems's EPS (Basic) for the three months ended in Mar. 2024 was $-0.31. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.21.
The historical data trend for Rapid Micro Biosystems's PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Micro Biosystems Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
PE Ratio | N/A | N/A | At Loss | At Loss | At Loss |
Rapid Micro Biosystems Quarterly Data | ||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
PE Ratio | Get a 7-Day Free Trial | At Loss | At Loss | At Loss | At Loss | At Loss |
For the Medical Devices subindustry, Rapid Micro Biosystems's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's PE Ratio distribution charts can be found below:
* The bar in red indicates where Rapid Micro Biosystems's PE Ratio falls into.
The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
Rapid Micro Biosystems's PE Ratio for today is calculated as
PE Ratio | = | Share Price | / | Earnings per Share (Diluted) (TTM) |
= | 0.80 | / | -1.210 | |
= | -0.66(At Loss) |
Rapid Micro Biosystems's Share Price of today is $0.80.
Rapid Micro Biosystems's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.21.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PE Ratio | = | Market Cap | / | Net Income |
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Rapid Micro Biosystems (NAS:RPID) PE Ratio Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.
Be Aware
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.
Thank you for viewing the detailed overview of Rapid Micro Biosystems's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Sean M Wirtjes | officer: Chief Financial Officer | C/O VARIAN, INC., 3120 HANSEN WAY, M/S D-083, PALO ALTO CA 94304-1030 |
Spignesi Robert G. Jr. | director, officer: President and CEO | C/O RAPID MICRO BIOSYSTEMS, INC., 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854 |
Kirk Malloy | director | 5200 ILLUMINA WAY, SAN DIEGO CA 92122 |
Kennedy Lewis Capital Partners Master Fund Ii Lp | 10 percent owner | 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120 |
Klm Gp Llc | 10 percent owner | 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004 |
Kennedy Lewis Capital Partners Master Fund Iii Lp | 10 percent owner | 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120 |
Kennedy Lewis Gp Ii Llc | 10 percent owner | 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120 |
Kennedy Lewis Gp Iii Llc | 10 percent owner | 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120 |
Kennedy Lewis Investment Holdings Ii Llc | 10 percent owner | 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120 |
Kennedy Lewis Investment Management Llc | 10 percent owner | 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004 |
Kennedy Lewis Management Lp | 10 percent owner | 225 LIBERTY STREET, SUITE 4210, NEW YORK NY 10281 |
David Chene | 10 percent owner | 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004 |
Darren Richman | 10 percent owner | 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004 |
Inese Lowenstein | director | C/O RAPID MICRO BIOSYSTEMS INC, 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854 |
Richard A Keys | officer: CHIEF COMMERCIAL OFFICER | C/O RAPID MICRO BIOSYSTEMS INC, 1001 PAWTUCKET BOULEVARD, SUITE 280, LOWELL MA 01854 |
From GuruFocus
By Value_Insider Value_Insider • 12-07-2022
By PurpleRose PurpleRose • 07-10-2022
By GlobeNewswire GlobeNewswire • 05-09-2023
By GuruFocus Research • 11-03-2023
By GuruFocus Research GuruFocus Editor • 05-19-2023
By Marketwired • 09-19-2023
By Marketwired • 07-18-2023
By Marketwired • 09-29-2023
By sperokesalga sperokesalga • 02-28-2023
By sperokesalga sperokesalga • 05-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.